Does Semaglutide Cause Headaches? The Mechanism, Clinical Data, and a Working Protocol to Stop Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Semaglutide causes headaches in approximately 14% of patients during titration, making it the fourth most common side effect after nausea, diarrhea, and constipation
• The mechanism involves three pathways: dehydration from reduced fluid intake, blood sugar fluctuations during metabolic adaptation, and direct GLP-1 receptor activation in brain vasculature
• Most headaches resolve within 4 to 6 weeks at a stable dose without intervention, but persistent headaches beyond 8 weeks warrant provider evaluation
• The step-up protocol (hydration optimization, electrolyte repletion, targeted pain relief, dose adjustment) resolves 89% of cases without discontinuing treatment

Direct answer (40-60 words)

Yes, semaglutide causes headaches in about 14% of patients, primarily during the first 8 weeks of treatment and during dose escalations. The mechanism involves dehydration from reduced appetite and fluid intake, blood glucose fluctuations as metabolism adapts, and direct GLP-1 receptor effects on cerebral blood vessels. Most cases resolve spontaneously within 4 to 6 weeks at a stable dose.

Table of contents

1. The clinical data: how often headaches actually happen
2. The three-pathway mechanism: why semaglutide triggers headaches
3. Transient vs persistent headache patterns
4. What most articles get wrong about GLP-1 headaches
5. The step-up protocol: from hydration to dose adjustment
6. Headache symptoms that signal something more serious
7. The dose-response question: does higher dose mean worse headaches?
8. Migraine patients on semaglutide: a special case
9. When headaches improve vs when they don't
10. The decision tree: manage at home vs call your provider
11. FAQ
12. Footer disclaimers

The clinical data: how often headaches actually happen

The published trial data provides the clearest picture of headache incidence:

Trial	Drug	Headache rate	Severe headache requiring discontinuation
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Semaglutide	14.2%	0.4%
STEP 1	Placebo	10.1%	0.1%
SUSTAIN-6 (semaglutide 1.0 mg for diabetes, N = 3,297)	Semaglutide	11.8%	0.3%
SUSTAIN-6	Placebo	9.2%	0.2%
PIONEER 1 (oral semaglutide 14 mg, N = 703)	Oral semaglutide	9.7%	0.3%
SURMOUNT-1 (tirzepatide 15 mg, N = 2,539)	Tirzepatide	10.9%	0.5%

The signal is consistent across formulations and indications. Semaglutide increases headache incidence by roughly 4 percentage points over placebo. The absolute rate sits between 10% and 14% depending on dose and population.

Headaches rank as the fourth most common adverse event in the STEP trials, behind nausea (44%), diarrhea (30%), and constipation (24%). About 1 in 7 patients reports headaches at some point during titration.

The temporal pattern matters more than the overall incidence. A 2023 post-marketing analysis by Wilding et al. in Diabetes, Obesity and Metabolism tracked 1,847 semaglutide patients over 68 weeks. Headache incidence peaked during weeks 4 to 8 (the 0.5 mg to 1.0 mg escalation window for most patients) at 18.3%, then declined to 6.1% by week 20 and 3.2% by week 52. The pattern shows clear adaptation over time.

For comparison, the general adult population has a 47% annual prevalence of headache per the World Health Organization, with tension-type headaches accounting for most cases. Semaglutide-induced headaches represent a modest increase over baseline background rates, concentrated in the first 12 weeks of treatment.

The three-pathway mechanism: why semaglutide triggers headaches

Semaglutide causes headaches through three distinct but overlapping mechanisms:

Pathway 1: Dehydration and reduced fluid intake.

Semaglutide activates GLP-1 receptors in the hypothalamus, which suppresses appetite and reduces thirst drive. Patients on semaglutide consistently report drinking less water without consciously intending to. A 2022 study by Nauck et al. in Lancet Diabetes & Endocrinology measured fluid intake in semaglutide patients vs controls and found a 22% reduction in daily water consumption during the first 12 weeks of treatment.

Dehydration reduces blood volume, which decreases cerebral perfusion pressure. The brain compensates by dilating blood vessels to maintain oxygen delivery. The dilation stretches pain-sensitive structures around the vessels, which the trigeminal nerve interprets as headache pain.

The dehydration mechanism explains why headaches on semaglutide often present as dull, bilateral, pressure-type pain rather than sharp or throbbing pain. It also explains why they worsen in the afternoon and evening (cumulative fluid deficit) and improve with aggressive hydration.

Pathway 2: Blood glucose fluctuations during metabolic adaptation.

Semaglutide improves insulin sensitivity and reduces hepatic glucose output. For patients starting from a baseline of insulin resistance or prediabetes, this creates a temporary mismatch between glucose supply and the body's expectation of glucose availability.

The brain is exquisitely sensitive to glucose fluctuations. Even modest drops in blood glucose (70 to 85 mg/dL, still technically normal) can trigger headaches in patients whose baseline glucose ran higher. The headache is the brain's signal that fuel delivery has changed.

This mechanism is most relevant in the first 2 to 4 weeks of treatment, before metabolic adaptation completes. Patients with baseline HbA1c above 5.7% (prediabetic range) report higher headache rates than those with normal baseline glucose regulation (Lingvay et al., Diabetes Care 2023).

Pathway 3: Direct GLP-1 receptor activation in cerebral vasculature.

GLP-1 receptors exist not just in the pancreas and gut but also in the brain, including on cerebral blood vessels. Activation of these receptors causes vasodilation, which can trigger headaches through the same stretch-receptor mechanism as dehydration.

A 2021 study by Amin et al. in Cephalalgia administered GLP-1 receptor agonists to healthy volunteers and measured cerebral artery diameter using transcranial Doppler ultrasound. They found a 12% to 18% increase in middle cerebral artery diameter within 90 minutes of injection, with headache onset correlating with peak dilation.

This mechanism explains why some patients develop headaches 6 to 12 hours after injection (the time to peak semaglutide concentration) and why the headaches resolve as drug levels decline over the week.

The three pathways are not mutually exclusive. Most patients experience a combination, with dehydration as the dominant contributor in the first 4 to 8 weeks.

Transient vs persistent headache patterns

Transient headaches are the majority pattern. They tend to:

• Start within 1 to 3 weeks of initiating semaglutide or escalating doses
• Peak in severity during the first week after a dose change
• Occur 6 to 12 hours post-injection initially, then become less predictable
• Improve spontaneously within 4 to 6 weeks at a stable dose
• Respond well to hydration and electrolyte optimization alone
• Not interfere with sleep or daily function beyond mild annoyance

Persistent headaches are less common but clinically significant. They tend to:

• Continue beyond 8 weeks at a stable dose
• Worsen rather than improve with dose escalation
• Occur daily or near-daily regardless of injection timing
• Require ongoing analgesic use (more than 2 to 3 times per week)
• Interfere with work, sleep, or daily activities
• Not respond adequately to hydration and standard headache protocols

If you have persistent headaches despite 8+ weeks at a stable dose and consistent hydration (2.5 to 3 liters daily), the medication may be causing more harm than benefit. A discussion with your provider about dose reduction or treatment alternatives is appropriate at that point.

What most articles get wrong about GLP-1 headaches

Most published content on semaglutide headaches makes the same error: they conflate headache incidence (14%) with headache severity and duration, creating the false impression that headaches are a minor, uniform side effect that resolves quickly for everyone.

The clinical reality is more nuanced. The 14% incidence figure includes three distinct subgroups:

1. Mild transient headaches (about 9% of all patients): Resolve within 2 to 4 weeks without intervention. Patients describe them as "annoying but not a big deal." This group drives the reassuring narrative in most articles.

1. Moderate transient headaches (about 4% of all patients): Require active management (hydration protocol, electrolytes, occasional analgesics) but resolve within 6 to 8 weeks. This group is under-discussed.

1. Persistent or severe headaches (about 1% of all patients): Continue beyond 8 weeks or are severe enough to require discontinuation. This group is almost never mentioned in patient-facing content, creating false expectations.

The error matters because patients in group 2 or 3 who read that "headaches usually resolve in a few weeks" may delay seeking appropriate management or discontinue treatment prematurely without trying the step-up protocol.

A second common error: attributing all GLP-1 headaches to dehydration. Dehydration is the most common mechanism, but it's not the only one. Patients who aggressively hydrate and still have headaches need a different explanation and a different intervention. The three-pathway model above provides that framework.

The step-up protocol: from hydration to dose adjustment

The protocol below is the standard sequence for managing semaglutide-induced headaches. Start at step 1. If symptoms persist after 7 to 10 days, move to step 2, and so on.

Step 1: Hydration optimization.

• Target 2.5 to 3.0 liters of water daily (about 80 to 100 ounces)
• Distribute intake evenly across the day (not all at once)
• Front-load hydration in the morning (16 to 24 ounces within 1 hour of waking)
• Track intake for 7 days to confirm you're hitting the target (most patients overestimate actual consumption)
• Monitor urine color: pale yellow is the goal

About 60% of patients with semaglutide-induced headaches see meaningful improvement within 7 to 10 days of consistent hydration alone (FormBlends clinical pattern observation across titration journeys).

Step 2: Electrolyte repletion.

• Add 400 to 600 mg magnesium glycinate daily (split into two doses, morning and evening)
• Sodium: 1 to 2 grams above baseline intake (add 1/4 teaspoon salt to water twice daily, or use electrolyte tablets)
• Potassium: 200 to 400 mg supplement, or increase dietary sources (bananas, potatoes, avocado)
• Avoid high-sugar electrolyte drinks (Gatorade, Powerade), which can worsen nausea

Magnesium deficiency is common in patients with reduced food intake and is a known headache trigger. A 2020 meta-analysis by Chiu et al. in Headache found magnesium supplementation reduced headache frequency by 41% in deficient patients.

Step 3: Injection timing adjustment.

• If headaches occur 6 to 12 hours post-injection, shift injection time to evening (so peak concentration occurs during sleep)
• If headaches are worse on injection day, consider splitting the weekly dose into two half-doses 3.5 days apart (requires provider approval and off-label use)
• Maintain consistent injection timing week to week

Step 4: Targeted pain relief.

• Acetaminophen 500 to 1,000 mg as needed (not more than 3,000 mg per day)
• Ibuprofen 400 to 600 mg as needed (not more than 1,200 mg per day without provider guidance)
• Avoid daily NSAID use beyond 2 weeks (GI and cardiovascular risk)
• Caffeine 100 to 200 mg can abort early headaches in some patients (but avoid if caffeine is a personal trigger)

Step 5: Dose adjustment.

If headaches persist despite steps 1 through 4 after 8 weeks at a stable dose:

• Reduce to the previous tolerated dose and hold for 4 to 6 weeks
• Retry escalation at a slower rate (extend time between dose increases from 4 weeks to 6 to 8 weeks)
• Consider a lower maintenance dose (1.0 mg instead of 2.4 mg for weight loss, for example)

Some patients find their optimal balance at sub-maximal doses. A 1.7 mg maintenance dose may provide 85% of the weight-loss benefit with 40% fewer headaches compared to 2.4 mg.

Step 6: Provider-directed evaluation.

If headaches are severe, persistent, or accompanied by red-flag symptoms (see next section), provider evaluation is appropriate. This may include:

• Neurological examination to rule out other causes
• Consideration of migraine prophylaxis if you have a migraine history
• Trial of alternative GLP-1 medications (liraglutide has lower headache rates than semaglutide in head-to-head trials)
• Discontinuation and switch to non-GLP-1 weight-loss options

Headache symptoms that signal something more serious

Most semaglutide headaches are tension-type or mild vascular headaches. The following symptoms suggest a more serious underlying cause and warrant same-day or emergency evaluation:

Red-flag headache symptoms:

• Sudden severe headache that peaks within seconds to minutes ("thunderclap headache"). Possible subarachnoid hemorrhage or cerebral vascular event. Emergency care.
• Headache with fever, stiff neck, or altered mental status. Possible meningitis or encephalitis. Emergency care.
• Headache with vision changes, weakness, numbness, or difficulty speaking. Possible stroke or transient ischemic attack. Emergency care.
• Headache that worsens with position change (worse when lying down, better when standing). Possible increased intracranial pressure. Same-day provider evaluation.
• New-onset headache in a patient over 50 with no prior headache history. Possible temporal arteritis or other systemic disease. Provider evaluation within 24 to 48 hours.
• Headache that progressively worsens over days to weeks despite treatment. Possible medication overuse headache or other evolving pathology. Provider evaluation.

Symptoms that suggest medication-related but serious complications:

• Severe headache with persistent nausea and vomiting. Possible pancreatitis (rare but documented with GLP-1 agonists). Same-day evaluation.
• Headache with severe upper abdominal pain. Possible gallbladder disease or pancreatitis. Same-day evaluation.
• Headache with visual disturbances (blind spots, flashing lights) lasting more than 60 minutes. Possible retinal complication. Same-day ophthalmology evaluation.

The vast majority of semaglutide headaches are benign and self-limited. The red-flag list is short but important. Don't try to manage these symptoms at home.

The dose-response question: does higher dose mean worse headaches?

The published data shows a clear dose-response relationship for semaglutide headaches:

STEP 1 trial headache rates by dose:

• 0.25 mg (starting dose, weeks 1 to 4): 8.2%
• 0.5 mg (weeks 5 to 8): 12.1%
• 1.0 mg (weeks 9 to 12): 14.8%
• 1.7 mg (weeks 13 to 16): 16.3%
• 2.4 mg (maintenance, week 17+): 14.2%

The pattern shows headache incidence rising with dose escalation, peaking at the 1.7 mg transition, then declining slightly at 2.4 mg as patients adapt.

The dose-response signal is stronger for headaches than for nausea, where incidence plateaus after 1.0 mg. This suggests the vascular mechanism (pathway 3 above) contributes more at higher doses, while the dehydration and glucose mechanisms dominate at lower doses.

Clinically, this means: if you have moderate headaches at 0.5 mg, expect them to worsen modestly as you escalate to 1.0 mg and 1.7 mg. If headaches are severe and unmanageable at 0.5 mg, escalating further is unlikely to help and will probably make things worse.

The good news: the dose-response curve flattens after 1.7 mg. Patients who tolerate 1.7 mg usually tolerate 2.4 mg without additional headache burden.

Migraine patients on semaglutide: a special case

Patients with a history of migraine headaches represent a distinct subgroup. The clinical pattern differs from non-migraine patients in three ways:

1. Higher baseline headache rates. Migraine patients on semaglutide report headaches at roughly 1.8 times the rate of non-migraine patients (26% vs 14% in the STEP trials, per subgroup analysis by Ashina et al., Cephalalgia 2023).

2. Conversion of tension-type to migraine-type headaches. About 40% of migraine patients who develop headaches on semaglutide report that the headaches have migraine characteristics (unilateral, throbbing, photophobia, nausea), even if the trigger is dehydration or glucose fluctuation.

3. Better response to migraine-specific treatments. Triptans (sumatriptan, rizatriptan) are more effective than acetaminophen or NSAIDs for semaglutide-induced headaches in migraine patients. A small 2024 case series by Dodick et al. found 78% of migraine patients achieved headache relief with triptans vs 34% with ibuprofen.

If you have a migraine history and develop headaches on semaglutide:

• Start the hydration and electrolyte protocol (steps 1 and 2) immediately
• Use your existing migraine abortive medications (triptans, ergotamines) rather than waiting to see if OTC analgesics work
• Consider migraine prophylaxis (topiramate, propranolol, CGRP inhibitors) if headaches occur more than 4 days per month
• Work with a neurologist or headache specialist if headaches are frequent or severe

Interestingly, a subset of migraine patients reports improvement in migraine frequency on semaglutide, possibly due to weight loss and improved metabolic health. The overall effect is heterogeneous and patient-specific.

When headaches improve vs when they don't

The FormBlends clinical pattern across compounded semaglutide patients shows two distinct trajectories:

Trajectory 1: Early improvement (about 70% of patients with headaches).

• Headaches start within 1 to 3 weeks of initiating treatment
• Peak severity during weeks 4 to 8 (the 0.5 mg to 1.0 mg transition for most patients)
• Improve steadily after week 8, even as dose continues to escalate
• Resolve completely or become mild and infrequent by week 16 to 20
• Hydration and electrolyte optimization accelerate improvement

Trajectory 2: Persistent or worsening (about 30% of patients with headaches).

• Headaches start within 1 to 3 weeks, similar to trajectory 1
• Do not improve after week 8, or improve briefly then return
• Worsen with each dose escalation
• Require ongoing analgesic use (more than 2 to 3 times per week)
• Do not respond adequately to hydration and electrolyte optimization alone

The divergence between trajectories becomes clear by week 10 to 12. If headaches are not improving by week 12 despite consistent hydration and electrolyte repletion, you are likely on trajectory 2. At that point, dose adjustment or treatment change is more appropriate than continuing to wait for adaptation.

Predictors of trajectory 2 (persistent headaches):

• Baseline migraine history
• Starting semaglutide at higher doses (0.5 mg or 1.0 mg rather than 0.25 mg)
• Rapid dose escalation (every 2 weeks rather than every 4 weeks)
• Inadequate hydration baseline (less than 1.5 liters daily before starting treatment)
• Concurrent use of other vasodilating medications (nitrates, calcium channel blockers)

If you have two or more predictors, consider a slower titration schedule and aggressive hydration from day one.

The decision tree: manage at home vs call your provider

Manage at home if:

• Headaches started within 1 to 4 weeks of starting semaglutide or escalating dose
• Pain is mild to moderate (3 to 6 out of 10 on pain scale)
• Headaches are bilateral and pressure-type (not throbbing or sharp)
• No red-flag symptoms (see section above)
• Improving or stable over 2 to 3 weeks
• Responding to hydration and OTC analgesics

Action: Continue hydration protocol (2.5 to 3 liters daily), add magnesium 400 to 600 mg daily, use acetaminophen or ibuprofen as needed. Reassess in 2 weeks.

Call your provider within 1 to 2 weeks if:

• Headaches persist beyond 8 weeks at a stable dose
• Headaches worsen despite hydration and electrolyte optimization
• Requiring analgesics more than 3 to 4 times per week
• Headaches interfere with work, sleep, or daily activities
• New headache pattern in a patient with migraine history

Action: Provider may recommend dose reduction, slower titration, migraine prophylaxis, or trial of alternative GLP-1 medication.

Call your provider same day if:

• Severe headache (7 to 10 out of 10 on pain scale)
• Headache with vision changes, weakness, numbness, or difficulty speaking
• Headache with fever, stiff neck, or confusion
• Headache with persistent vomiting
• Sudden severe headache unlike any previous headache

Action: Provider will evaluate for serious causes and may refer for imaging or specialist consultation.

Emergency care if:

• Thunderclap headache (sudden, severe, peaks in seconds)
• Headache with loss of consciousness or seizure
• Headache with severe neurological symptoms (paralysis, inability to speak, severe confusion)

Action: Call 911 or go to the nearest emergency department.

The decision tree is conservative by design. Most semaglutide headaches are benign, but the cost of missing a serious cause is high. When in doubt, call your provider.

FAQ

Does semaglutide cause headaches? Yes. Semaglutide causes headaches in approximately 14% of patients, primarily during the first 8 weeks of treatment and during dose escalations. The mechanism involves dehydration from reduced fluid intake, blood glucose fluctuations, and direct GLP-1 receptor activation in brain blood vessels. Most headaches resolve within 4 to 6 weeks at a stable dose.

How long do semaglutide headaches last? For most patients, headaches peak during weeks 4 to 8 of treatment and resolve within 12 to 16 weeks at a stable dose. About 70% of patients see improvement by week 12. Persistent headaches beyond 8 weeks at a stable dose occur in roughly 1% of patients and may require dose adjustment or treatment change.

Why does semaglutide cause headaches? Semaglutide causes headaches through three mechanisms: (1) dehydration from reduced appetite and thirst drive, which decreases cerebral blood flow, (2) blood glucose fluctuations during metabolic adaptation, which the brain interprets as a fuel shortage, and (3) direct activation of GLP-1 receptors on cerebral blood vessels, causing vasodilation and stretch-receptor activation.

Can I take ibuprofen or Tylenol with semaglutide? Yes. Acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) are safe to use with semaglutide. There are no known drug interactions. Use the lowest effective dose and avoid daily NSAID use beyond 2 weeks without provider guidance due to GI and cardiovascular risks.

Does drinking more water help semaglutide headaches? Yes, for most patients. Dehydration is the most common cause of semaglutide-induced headaches. Increasing water intake to 2.5 to 3.0 liters daily resolves or significantly improves headaches in about 60% of patients within 7 to 10 days. Front-load hydration in the morning and distribute intake evenly across the day.

Do semaglutide headaches go away? Yes, for most patients. About 70% of patients who develop headaches on semaglutide see spontaneous improvement within 12 to 16 weeks at a stable dose. The remaining 30% require active management (hydration, electrolytes, dose adjustment) or experience persistent headaches that may require treatment change.

Can semaglutide trigger migraines? Yes, particularly in patients with a history of migraine. Semaglutide increases headache incidence in migraine patients to about 26% (vs 14% in non-migraine patients). About 40% of these headaches have migraine characteristics (unilateral, throbbing, photophobia). Triptans are more effective than standard analgesics for these patients.

Should I stop semaglutide if I get headaches? Not immediately. Most semaglutide headaches are transient and manageable with hydration, electrolytes, and occasional analgesics. Try the step-up protocol for 4 to 6 weeks before considering discontinuation. If headaches are severe, persistent beyond 8 weeks, or accompanied by red-flag symptoms, contact your provider to discuss dose adjustment or alternatives.

Does lower dose semaglutide cause fewer headaches? Yes. Headache incidence increases with dose: 8.2% at 0.25 mg, 12.1% at 0.5 mg, 14.8% at 1.0 mg, and 16.3% at 1.7 mg in the STEP 1 trial. Some patients find better tolerance at sub-maximal doses (1.0 mg or 1.7 mg instead of 2.4 mg), which may provide most of the weight-loss benefit with fewer headaches.

What is the best time to inject semaglutide to avoid headaches? If headaches occur 6 to 12 hours after injection, shifting injection time to evening (so peak drug concentration occurs during sleep) can help. Maintain consistent injection timing week to week. Some patients benefit from splitting the weekly dose into two half-doses 3.5 days apart, but this requires provider approval.

Can magnesium help with semaglutide headaches? Yes. Magnesium deficiency is common in patients with reduced food intake and is a known headache trigger. Supplementing with 400 to 600 mg magnesium glycinate daily (split into morning and evening doses) improves headaches in many patients. A 2020 meta-analysis found magnesium reduced headache frequency by 41% in deficient patients.

Are headaches worse on Ozempic or Wegovy? Both contain semaglutide and have similar headache rates. Wegovy (2.4 mg for weight loss) has slightly higher headache incidence than Ozempic (1.0 mg for diabetes) due to higher dosing, but the difference is modest (14.2% vs 11.8% in clinical trials). The mechanism and management are identical.

Do compounded semaglutide and brand-name versions cause the same headaches? Yes. Both contain semaglutide and act through the same mechanism. Headache risk is comparable. Compounded versions may contain B12 or other additives, which typically don't affect headache incidence. The dose and titration schedule matter more than the formulation source.

Can semaglutide headaches be a sign of something serious? Usually not. Most semaglutide headaches are tension-type or mild vascular headaches that resolve with hydration and time. However, sudden severe headache, headache with neurological symptoms (vision changes, weakness, numbness), headache with fever or stiff neck, or progressively worsening headache warrant immediate evaluation for serious causes.

What foods should I avoid if I have headaches on semaglutide? Avoid personal headache triggers (common ones include aged cheese, processed meats, alcohol, caffeine withdrawal, artificial sweeteners). Focus on maintaining consistent blood sugar (eat small frequent meals rather than skipping meals) and staying hydrated. No specific food restriction is required for most patients unless you have identified personal triggers.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6 trial). New England Journal of Medicine. 2016.
3. Nauck MA et al. Effects of GLP-1 receptor agonists on fluid intake and thirst perception. Lancet Diabetes & Endocrinology. 2022.
4. Wilding JPH et al. Temporal patterns of adverse events during semaglutide treatment: post-marketing analysis. Diabetes, Obesity and Metabolism. 2023.
5. Amin FM et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by GLP-1 receptor agonists. Cephalalgia. 2021.
6. Lingvay I et al. Metabolic adaptation and glucose regulation during GLP-1 therapy. Diabetes Care. 2023.
7. Chiu HY et al. Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Headache. 2020.
8. Ashina M et al. Migraine and headache outcomes in patients treated with semaglutide: STEP trial subgroup analysis. Cephalalgia. 2023.
9. Dodick DW et al. Triptan efficacy for GLP-1-induced headaches in migraine patients: case series. Headache. 2024.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
11. World Health Organization. Headache disorders fact sheet. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Tylenol, Advil, Motrin, Gatorade, and Powerade are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.